ORIGINAL ARTICLESIn vitro and in vivo effects of polyhaemoglobin–tyrosinase on murine B16F10 melanomaYu, Binglan; Swi Chang, Thomas MingAuthor Information Artificial Cells and Organs Research Center, Faculty of Medicine, McGill University, Montreal, Quebec, Canada H3G 1Y6 Sponsorship: This work was supported by operating grants (T.M.S. Chang) and a studentship award (B.Yu) from the Medical Research Council of Canada and the Canadian Institutes of Health Research. Correspondence and requests for reprints to Professor Thomas Ming Swi Chang, Director, Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University, 3655 Drummond Street, Room 1006, Montreal, Quebec, Canada H3G 1Y6 Tel: +1 514 398 3512; fax: +1 514 398 4983; e-mail: [email protected] Received 25 September 2003 Accepted 16 April 2004 Melanoma Research: June 2004 - Volume 14 - Issue 3 - p 197-202 doi: 10.1097/01.cmr.0000131013.71638.c0 Buy Metrics Abstract Melanoma is an increasingly common fatal skin cancer. Many groups are carrying out research on potential treatments for melanoma. One of these approaches has shown that lowering tyrosine can inhibit the growth of melanoma in cell cultures and of B16BL6 melanoma in mice. However, humans cannot tolerate tyrosine-restricted diets for lowering tyrosine because of nausea, vomiting and weight loss. We report here our preparation and characterization of a novel soluble polyhaemoglobin–tyrosinase complex. This preparation prevents native tyrosinase from having adverse effects and from rapid removal after injection. The preparation inhibited murine B16F10 melanoma cell growth in culture and delayed its growth in a mice model. Intravenous injection of the preparation lowers the systemic tyrosine level without causing adverse effects such as vomiting and weight loss in mice. It is therefore possible that this complex could be useful in the treatment of human melanoma. © 2004 Lippincott Williams & Wilkins, Inc.